Dice CEO: Energy, T...
Health Care: Drugs
Elan Corp PLC (ELN: NYSE)
$13.39 -0.57 | -4.08%
06/01/12 - 04:03 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 560.50M | -324.70M | -176.20M | -71.00M |
| Operating Gains/Losses | -575.30M | -11.00M | -103.10M | 1.60M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 23.90M | 800.00K | 3.70M | -58.70M |
| (Increase) Decrease in Inventories | 15.20M | 14.20M | -24.30M | 6.90M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -213.50M | 33.00M | 29.90M | 22.70M |
| (Decrease) Increase In Other Current Liabilities | -6.90M | -700.00K | 4.30M | -1.30M |
| (Increase) Decrease In Other Working Capital | -70.90M | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | 108.40M | 277.50M | 115.90M | 70.80M |
| Net Cash From Continuing Operations | -120.20M | 68.20M | -86.30M | -194.30M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -120.20M | 68.20M | -86.30M | -194.30M |
| Sale of Property, Plant & Equipment | 1.30M | 100.00K | 7.30M | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 300.00K | 8.50M | 28.90M | 232.60M |
| Purchases of Property, Plant & Equipment | -29.80M | -44.50M | -95.90M | -137.90M |
| Acquisitions | 500.00M | 0.00 | 0.00 | 2.00M |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 186.80M | -187.10M | 3.50M | -5.60M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 660.50M | -216.00M | -56.80M | 94.50M |
| Issuance of Debt | 0.00 | 187.10M | 603.00M | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 0.00 | 0.00 | 872.00M | 50.00M |
| Repayment of Long-Term Debt | -697.30M | -455.00M | -867.80M | -900.00K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 6.30M | 1.80M | -3.10M | 2.40M |
| Net Cash From Financing Activities | -691.00M | -266.10M | 604.10M | 51.50M |
| Effect of Exchange Rate Changes | -100.00K | -100.00K | 200.00K | 100.00K |
| Net Change in Cash & Cash Equivalents | -150.80M | -414.00M | 461.20M | -48.20M |
Portfolios with ELN
- Portfolio NameUser Type
- Contributor22 Biopharma Stocks With Br...
- ProGeorge Soros
- UserGFNN Stockdiagnostics 13
- ContributorBreakout Stocks Of The Week...
- UserGFNN Stockdiagnostics
- ContributorRelative Strength Trades fo...
- ContributorStocks At New 52-Week Highs...
- ProRobert Bruce
- ContributorTechnical Setups for the We...
- Contributor10 Health Care Stocks With ...
Latest ELN Headlines from TheStreet
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- A Health Care Fortnight for the Record Books 05.14.12 | 07:05 am
- On Nowruz, Reviewing Drug Stock Picks 03.26.12 | 07:03 am
- Elan's Alzheimer's-Fueled Run Means Investors Are Forgetting the Past 03.19.12 | 07:03 am
- The Case for Shorting Elan Into Upcoming Alzheimer's Trial Results 02.21.12 | 07:02 am
- Medivation Shrugs Off Alzheimer's Setback as Investors Eye New Prostate Cancer Data 01.17.12 | 09:01 am
- 7 Relative Strength Stocks for 2012 12.29.11 | 05:12 pm
- 7 Stocks Hitting New 52-Week Highs 12.21.11 | 01:12 pm
- Your Vote Counts: Who is the Worst Biotech CEO of 2011? 12.01.11 | 10:12 am
- Good Biotech Stocks for a Bear Market 08.09.11 | 08:08 am
Press Releases for ELN
- Elan To Present At Jefferies 2012 Global Healthcare Conference - Business Wire 05.28.12 | 08:05 am
- New Analysis Of Risk Stratification For TYSABRI® Published In New England Journal Of Medicine - Business Wire 05.17.12 | 03:05 pm
- Elan Reports First Quarter 2012 Financial Results - Business Wire 04.26.12 | 02:04 am
- Elan Announces Webcast Of First Quarter 2012 Financial Results - Business Wire 04.12.12 | 04:04 pm
- Elan Raises $381 Million In Sale Of 76% Of Alkermes Holding - Business Wire 03.13.12 | 12:03 pm
- Elan Chairman Provides Update On CEO Succession - Business Wire 03.01.12 | 02:03 am
- Elan Reports Fourth Quarter And Full-Year 2011 Financial Results - Business Wire 02.08.12 | 02:02 am
- Elan To Present At The Leerink Swann 2012 Global Healthcare Conference - Business Wire 02.01.12 | 04:02 pm
- ASCEND Study To Evaluate The Effectiveness Of TYSABRI® (natalizumab) As A Treatment For Secondary-Progressive Multiple Sclerosis - Business Wire 01.26.12 | 08:01 am
- FDA Updates TYSABRI® (natalizumab) Label To Include Anti-JC Virus Antibody Status As A PML Risk Factor - Business Wire 01.20.12 | 04:01 pm
Partner Headlines for ELN
- Healthcare Biz Recap: Express Scripts New Driver, Elan Pops - Wall St. Cheat Sheet 05.27.12 | 12:05 pm
- Billionaire Soros' Q1 High Conviction Buys In 2 Growth Stocks, Other Buys And Sells - Seeking Alpha 05.18.12 | 08:05 pm
- Revenues Climb at Acorda - Analyst Blog - Zacks 05.04.12 | 06:05 pm
- Elan Misses 1Q EPS, Revenues Rise - Analyst Blog - Zacks 05.01.12 | 09:05 am
- Elan Sells 76% Stake in Alkermes - Analyst Blog - Zacks 03.16.12 | 05:03 pm
- Tuesday's Bio Pharma Watch List - Seeking Alpha 02.28.12 | 08:02 am
- Zacks Sell List Highlights: Expedia, NII Holdings, Elan and Gentex - Press Releases - Zacks 02.17.12 | 09:02 am
- NII HLDGS-CL B (NIHD) - Profit Tracks - Zacks 02.17.12 | 01:02 am
- The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company - Press Releases - Zacks 02.06.12 | 09:02 am
- The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche - Press Releases - Zacks 02.01.12 | 09:02 am
